866-997-4948(US-Canada Toll Free)

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 65 Pages

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2016, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 2 respectively.End-Stage Kidney Disease.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 6
Therapeutics Development 7
Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 7
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Development by Companies 8
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Development by Companies 12
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development 13
Acceleron Pharma Inc 13
BioAegis Therapeutics Inc 14
BLR Bio LLC 15
Bristol-Myers Squibb Company 16
CTI BioPharma Corp 17
F. Hoffmann-La Roche Ltd 18
Prolong Pharmaceuticals LLC 19
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
BLR-400 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BMS-986177 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
calcium succinate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
obinutuzumab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
pacritinib - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Sanguinate - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
sotatercept - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects 59
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products 60
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones 61
Featured News & Press Releases 61
Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 61
Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis 61
Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting 62
Dec 18, 2013: Acceleron Earns $7 Million Milestone Payment for Celgenes Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acceleron Pharma Inc, H2 2016 13
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, H2 2016 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BLR Bio LLC, H2 2016 15
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bristol-Myers Squibb Company, H2 2016 16
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by CTI BioPharma Corp, H2 2016 17
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 18
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals LLC, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H2 2016 59
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H2 2016 60

List of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Top 10 Targets, H2 2016 21
Number of Products by Stage and Top 10 Targets, H2 2016 21
Number of Products by Top 10 Mechanism of Actions, H2 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *